Uncategorized

The neurostimulation device company intends to offer 10 million shares for between $14 and $16 each.

El cerdo extinto Cainochoerus vivió en el este de África durante el Mioceno, hace unos 6 millones de años, y era mucho más pequeño que los cerdos africanos actuales. Ahora, un equipo de investigación en paleontología ha descubierto mandíbulas y …

The action affects BioNTech sites in Germany and Singapore, where the company expects to have excess capacity.

Madrigal Pharmaceuticals has licensed from Arrowhead Pharmaceuticals an RNA interference candidate that targets a genetic mutation present in around 30% of patients with MASH.

WakeMed would become part of Advocate Health, Atrium’s parent company. The deal has sparked concern from local lawmakers, who worry it could raise healthcare prices in North Carolina’s most populous county.

Despite the continued decline of Pfizer’s COVID-19 products, shares stayed stable on Tuesday morning after the New York pharma reported a first quarter beat, which was led by Eliquis and Ibrance.

Biogen’s Qalsody won FDA approval in 2023 to treat a rare, genetic form of amyotrophic lateral sclerosis. On Tuesday, QurAlis presented interim Phase 2 data showing the potential of a similar drug to more broadly treat the neurodegenerative disease.

The selloff in Eli Lilly’s shares was “overdone,” according to RBC Capital Markets, which noted that the overall safety profile of Foundayo remains favorable.

While some analysts may regard Vertex Pharmaceuticals’ first quarter results as “unremarkable,” BMO Capital Markets wrote on Monday, the second half of 2026 could be big for the biotech, with the potential approval of IgAN therapy povetacicept.

The FDA is reportedly down to a handful of final candidates to lead CBER, with a potential selection expected in the coming month or two. For now, the appointment of acting director Katherine Szarama has not allayed the industry’s concerns.